Sanjiu Investment To Acquire China Resources Dong E E Jiao
This article was originally published in PharmAsia News
In its ambition to forge a centralized pharmaceutical platform, state-owned China Resources National Corp. has transferred its 56.619 percent stake in China Resources Dong E E Jiao to New Sanjiu Holding's investment management arm. In return, CRNC will acquire the equities of Sanjiu Enterprise Group from the holding company. Industry analysts observe that the move is not consistent with CRNC's original plan of operating Sanjiu's pharmaceutical business and Dong E E Jiao's health care products separately. However, with Dong E E Jiao now under New Sanjiu, it appears that CRNC intends to reorganize its strategy by integrating both businesses. (Click here for more - Chinese Language)
You may also be interested in...
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.